PNC's $166.63B Q4 Filing Is Really an Eli Lilly Story: One Stock at 33.57%

PNC Financial Services Group reported $166.63B in canonical Q4 2025 13F AUM, but one number overwhelms everything else: Eli Lilly (LLY) at $54.94B, or 33.57% of the portfolio. For most institutional filings, the headline is top-5 diversification; here, the headline is single-name gravity.

TL;DR

• Canonical AUM: $166.63B in 2025Q4.
• Holdings snapshot: 500 positions in the current output.
• Dominant position: LLY at $54.94B and 33.57% weight.
• Concentration profile: Top-5 at 46.2% and top-10 at 51.8%.
• Quarter trend: AUM rose from $148.57B (2025Q3) to $166.63B (2025Q4), +12.2% QoQ.
• Second anchor: IVV at $10.20B (6.23%), far below the LLY scale.
• Read-through: The filing behaves like a diversified platform wrapped around one outsized conviction.

Filing Snapshot

PNC’s generated brief shows canonical AUM at $166.63B, holdings value sum at $163.65B, and WhaleScore at 75.75. The manager has also trended upward through 2025, with a strong finish into Q4.

The Core Signal: LLY as Portfolio Center of Gravity

At 33.57% weight, LLY carries more exposure than the next several disclosed positions combined. That creates a structurally different risk profile from peers where top names typically cluster below 5% each.

After LLY and IVV, the book quickly transitions to smaller weights in Apple (AAPL), Microsoft (MSFT), Alphabet (GOOGL), and SPY. The distribution indicates that diversification exists, but it operates around a very large biotech anchor.

AUM Momentum Is Real, But It Doesn’t Dilute Concentration

From $128.55B in 2024Q1 to $166.63B in 2025Q4, the AUM path reflects steady expansion with accelerating growth late in 2025. Yet even as asset base grows, the concentration profile remains dominated by the top LLY line item.

What This Means for Smart-Money Tracking

If you follow 13F filings to map institutional conviction, this is a high-signal case. PNC’s disclosure suggests a manager comfortable carrying substantial idiosyncratic exposure while still preserving broad market and factor sleeves through ETFs and mega-cap equities.

Label Caveat for Large Filers

The source can label many holdings as “NEW position” in ways that do not always represent first-time ownership. For this filing, concentration math and weight distribution are the critical interpretation tools.

Q&A

Why is PNC’s Q4 2025 filing unusual versus other large managers?

Because one position, LLY, represents 33.57% of disclosed portfolio weight, which is far above typical top-position concentration for a manager this size.

Did PNC grow assets in Q4 2025?

Yes. Canonical AUM moved from $148.57B in 2025Q3 to $166.63B in 2025Q4, a +12.2% QoQ increase in the history series.

What is the second-largest disclosed position after LLY?

IVV at $10.20B and 6.23% weight, substantially smaller than the LLY allocation.

Is this filing only a biotech bet?

No. The rest of the book includes broad index exposure and mega-cap technology, but those sleeves are much smaller than the dominant LLY position.

Where should I monitor follow-through in future quarters?

Track the filer page and key names: PNC, LLY, IVV, AAPL, and MSFT.